The FDA approved a new at-home starting dose for Leqembi Iqlik (lecanemab-irmb) on July 13, 2026, letting people with early Alzheimer's begin treatment with a subcutaneous injection instead of starting on IV infusions in a clinic. Leqembi Iqlik is the injectable, under-the-skin form of lecanemab, an anti-amyloid drug that targets the protein buildup linked to Alzheimer's disease. This approval means the entire course of treatment, from the first dose through ongoing maintenance, can now happen at home. The checklist below covers who qualifies, what the weekly injection involves, and what to have ready before the first dose.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
- Explore the official data from FDA — Use this primary source to review the underlying data.
Table of Contents
- What Changed, and Who Qualifies
- How the Starting Dose Works
- Safety Steps Before the First Injection
- Preparation Checklist for the First At-Home Dose
- Setting Up for Ongoing Weekly Dosing
- Frequently Asked Questions
What Changed, and Who Qualifies
The FDA's approval of the at-home starting dose removes a requirement that had been in place since Leqembi Iqlik's first clearance. The drug was originally approved in August 2025 only for maintenance dosing, meaning a patient had to complete 18 months of biweekly IV infusions of standard Leqembi before switching to the injectable version. The 2026 approval eliminates that IV-first step entirely. Eisai and Biogen, which co-market the drug, say Leqembi Iqlik is now the first anti-amyloid Alzheimer's medicine approved anywhere for at-home dosing across the full treatment course, from day one through ongoing maintenance.
That is a meaningful shift from infusion-center visits to a treatment a patient or caregiver can manage at home. Eligibility has not changed from the existing Leqembi label. The drug is indicated for people with mild cognitive impairment or mild dementia due to Alzheimer's disease who have confirmed amyloid pathology, consistent with the existing approval criteria. A diagnosis of moderate or advanced Alzheimer's does not qualify, and amyloid pathology must be confirmed, typically through a PET scan or cerebrospinal fluid test, before starting.
How the Starting Dose Works
The approved starting regimen is 500 mg given once weekly, delivered as two separate 250 mg subcutaneous injections. Each injection takes about 15 seconds to administer, and either the patient or a caregiver can give it at home. This weekly schedule replaces the biweekly IV infusions that previously had to come first.
Clinical support for the switch came from sub-studies within the Clarity AD phase 3 trial and its open-label extension, which showed that weekly 500 mg subcutaneous dosing produces blood levels of the drug comparable to the biweekly IV infusion, with similar clinical, biomarker, and safety results, including rates of ARIA (amyloid-related imaging abnormalities, a brain-swelling or microbleed side effect associated with this drug class). After an initial period on the starting dose, patients transition to the maintenance regimen that was already approved in 2025: 360 mg once weekly. The injection method stays the same; only the dose changes.
Safety Steps Before the First Injection
Leqembi Iqlik carries a boxed warning, the FDA's strongest safety alert, for ARIA. Because of this, prescribers are directed to test a patient's ApoE ε4 genotype before starting treatment, since this gene variant helps estimate an individual's ARIA risk. Genotype testing is not mandatory to begin therapy, but it gives the care team information to monitor more closely if risk is elevated. Because the drug is now given as an injection rather than an infusion, the side-effect profile shifts accordingly.
The most common side effects are localized injection-site reactions, including redness, swelling, rash, pain, and bruising, rather than the infusion-related reactions seen with IV dosing. These reactions are typically managed by rotating injection sites and monitoring the area after each dose. The prescribing information also requires an ongoing safety check beyond the first dose: clinicians are directed to have patients and caregivers review the official Instructions for Use, and to periodically reassess whether the patient or caregiver can still safely prepare and administer the injection at home. This reassessment matters especially as Alzheimer's symptoms progress, since the skills needed to safely self-inject may change over time.
Preparation Checklist for the First At-Home Dose
Before the first injection, patients and caregivers should confirm a few practical steps drawn from the drug's prescribing information: These steps come directly from the drug's prescribing information. Following them in order reduces both the chance of a wasted dose and the chance of an avoidable injection-site reaction.
- Remove the autoinjector from the refrigerator about 20 minutes before injecting, to let it reach room temperature.
- Never use an external heat source, such as a hair dryer or warm water, to speed up warming.
- Check the solution visually before injecting; discard the injection if it looks cloudy, discolored, or contains visible particles.
- Rotate injection sites among the abdomen, thigh, and back of the upper arm to reduce site reactions.
- Keep the Instructions for Use on hand for the first several doses, and revisit it anytime technique is uncertain.
Setting Up for Ongoing Weekly Dosing
Because dosing is weekly and ongoing, it helps to build a routine before the first injection rather than after. Picking a consistent day and time each week, and marking it on a calendar or in a phone reminder, can prevent missed or doubled doses, since the schedule has no infusion-center visit to anchor it.
A caregiver who will be giving the injection should practice the technique with a member of the care team present at the first dose, if possible, rather than attempting it alone for the first time. Because the prescriber will periodically reassess whether a patient or caregiver can still safely administer the injection, keeping notes on how each dose went, including any site reactions, gives that follow-up conversation something concrete to work from.
Frequently Asked Questions
Does the at-home starting dose replace IV infusions entirely?
For patients starting fresh, yes. The July 2026 approval removes the prior requirement of 18 months of biweekly IV infusions before switching to the injectable form, so treatment can begin and continue entirely at home.
Is genetic testing required before starting?
No. ApoE ε4 genotype testing is recommended to help estimate ARIA risk, but it is not mandatory before beginning treatment.
How is the starting dose different from the maintenance dose?
The starting dose is 500 mg weekly, given as two 250 mg injections. After the initial period, patients move to the previously approved maintenance dose of 360 mg weekly, using the same injection method.
You Might Also Like
- AAIC 2026 LatAm-FINGERS Cognitive Health Results: Questions People With Mild Cognitive Impairment Can Discuss With a Clinician
- Maine’s 2026 ECHO Training for Dementia Risk Reduction: Data Questions Family Caregivers Should Ask
- LiBBY Trial Findings for Late-Stage Dementia Agitation in 2026: Study Design and Evidence Limits for People With Mild Cognitive Impairment
